ENET & MDG Boston: The Path Forward after COVID-19 for Life Science Startup Companies

Join CBSET at a free online webinar: The Path Forward after COVID-19 for Life Science Startup Companies, hosted jointly by ENET and MDG Boston, on July 14th at 7:00 pm.

While the trend in Massachusetts indicates that COVID-19 infections are abating, it seems increasingly clear that this pandemic crisis will be with us for a while. The disruption to business as usual is obvious and the existential threat to small businesses is real.

In spite of having been designated essential businesses, life sciences enterprises, especially startups and early-stage companies, are facing significant challenges.

ENET and MDG-Boston have assembled a panel of industry leaders who will share their thoughts on how life sciences companies can plan a coherent path forward through the remainder of the COVID-19 inspired disruptions and beyond.

(Capacity is limited so pre-registration is necessary.)


Related CBSET Services:

livestreamingLearn more about our live video streaming capabilities.

 

Please contact us to schedule an e-meeting before, during or after the July 14th ENET/MDG Event.









Related CBSET Services:


Related Publications:

Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings. Tzafriri AR, Garcia-Polite F, Li X, Keating J, Balaguer JM, Zani B, Bailey L, Markham P, Kiorpes TC, Carlyle W, Edelman ER. Journal of Controlled Release. Volume 274, 28 March 2018, Pages 102-108

Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosisAbraham R. Tzafriri, Fernando Garcia-Polite, Brett Zani, James Stanley, Benny Muraj, Jennifer Knutson, Robert Kohler, Peter Markham, Alexander Nikanorov, Elazer R. Edelman. Journal of Controlled Release, Volume 264, 28 October 2017, Pages 203-210.

A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials: A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044.